Despite recent advances in colorectal cancer treatment, the prognosis of patients suffering from this malignancy still remains substandard, and metastatic recurrence following curative surgery is the leading cause of mortality.
Therefore, it is imperative to identify prognostic markers to predict the clinical outcome of colorectal cancer patients.
Recent evidence revealed the new role of small nucleolar RNAs (snoRNAs) in oncogenesis.
Herein, Dr Ajay Goel and colleagues from Texas, USA systematically evaluated dysregulation of snoRNAs in colorectal cancer, and clarified their biomarker potential and biological significance in colorectal cancer.
The researchers analyzed expression levels of 4 snoRNAs in 274 colorectal tissues from 3 independent cohorts and 6 colon cancer cell lines.
|SNORA42 expression was an independent prognostic factor for overall survival |
The functional characterization for the role of SNORA42 in colorectal cancer was investigated through a series of in vitro and in vivo experiments.
In the screening phase, expression levels of all 4 snoRNAs were significantly elevated in colorectal cancer tissues than in corresponding normal mucosa.
In the clinical validation cohort, increased SNORA42 expression was an independent prognostic factor for overall survival and disease-free survival, and was a risk factor for distant metastasis.
The research team found that the SNORA42 expression negatively correlated with overall survival in an additional independent cohort and identified the patients with high risk for recurrence and poor prognosis in stage II colorectal cancer.
The team showed that SNORA42 overexpression resulted in enhanced cell proliferation, migration, invasion, anoikis resistance and tumorigenicity.
Dr Goel's team comments, "SNORA42 appears to be a novel oncogene and could serve as a promising predictive biomarker for recurrence and prognosis in patients with colorectal cancer."